Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

James Levine Biography and Net Worth

CFO of Cardiff Oncology

Mr. Levine has served as Chief Financial Officer since 2021. Mr. Levine has extensive corporate and investment banking experience with both private and public biotechnology and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of important pre-clinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson & Johnson) and Mundipharma with a combined value of over $1.3 billion. Previously, Mr. Levine was the president and chief executive officer of Sapphire Energy Inc., a private industrial biotechnology company that was sold to two private investor groups. He also previously served in the same roles at Verenium Corp., where he negotiated six product commercialization partnerships and asset sales, before selling the company to BASF. He also previously was a managing director in the investment banking division of Goldman Sachs & Co., serving in its healthcare and energy groups.

Mr. Levine earned an MBA in finance from the Wharton School of the University of Pennsylvania and a BA in economics from Brandeis University.

What is James E. Levine's net worth?: The estimated net worth of James E. Levine is at least $255,600.00 as of September 16th, 2022. Mr. Levine owns 60,000 shares of Cardiff Oncology stock worth more than $255,600 as of December 22nd. This net worth evaluation does not reflect any other investments that Mr. Levine may own. Additionally, Mr. Levine receives a salary of $642,040.00 as CFO at Cardiff Oncology. Learn More about James E. Levine's net worth.
How old is James E. Levine?: Mr. Levine is currently 53 years old. There are 3 older executives and no younger executives at Cardiff Oncology. The oldest executive at Cardiff Oncology is Dr. Fairooz Kabbinavar FACP, M.D., Chief Medical Officer, who is 67 years old. Learn More on James E. Levine's age.
What is James E. Levine's salary?: As the CFO of Cardiff Oncology, Inc., Mr. Levine earns $642,040.00 per year. There are 3 executives that earn more than Mr. Levine. The highest earning executive at Cardiff Oncology is Dr. Tod Smeal Ph.D., Chief Scientific Officer?, who commands a salary of $2,690,000.00 per year. Learn More on James E. Levine's salary.
How do I contact James E. Levine?: The corporate mailing address for Mr. Levine and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]. Learn More on James E. Levine's contact information.
Has James E. Levine been buying or selling shares of Cardiff Oncology?: James E. Levine has not been actively trading shares of Cardiff Oncology within the last three months. Most recently, on Friday, September 16th, James E. Levine bought 30,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $1.56 per share, with a total value of $46,800.00. Following the completion of the transaction, the chief financial officer now directly owns 60,000 shares of the company's stock, valued at $93,600. Learn More on James E. Levine's trading history.
Who are Cardiff Oncology's active insiders?: Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.
Are insiders buying or selling shares of Cardiff Oncology?: In the last year, Cardiff Oncology insiders bought shares 1 times. They purchased a total of 350,115 shares worth more than $910,299.00. The most recent insider tranaction occured on December, 11th when Director Gary W Pace bought 350,115 shares worth more than $910,299.00. Insiders at Cardiff Oncology own 7.8% of the company. Learn More about insider trades at Cardiff Oncology.
Information on this page was last updated on 12/11/2024.

James E. Levine Insider Trading History at Cardiff Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2022	Buy	30,000	$1.56	$46,800.00	60,000
9/10/2021	Buy	30,000	$6.47	$194,100.00	5,000

James E. Levine Buying and Selling Activity at Cardiff Oncology

Cardiff Oncology Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $4.26

$4.20

$4.67

50 Day Range

MA: $3.08

$2.31

$5.35

2 Week Range

Now: $4.26

$1.41

$6.42

Volume

2,098,097 shs

Average Volume

1,215,761 shs

Market Capitalization

$217.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

The #1 Coin for November 2024

From Crypto 101 Media | Ad

You can get access to the report by clicking here now…

James Levine Biography and Net Worth

What is James E. Levine's net worth?

How old is James E. Levine?

What is James E. Levine's salary?

How do I contact James E. Levine?

Has James E. Levine been buying or selling shares of Cardiff Oncology?

Who are Cardiff Oncology's active insiders?

Are insiders buying or selling shares of Cardiff Oncology?